RIGL Stock Risk & Deep Value Analysis
Rigel Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About RIGL Stock
We analyzed Rigel Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RIGL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
RIGL Risk Analysis & Red Flags
What Could Go Wrong
Despite recent profitability, Rigel's future cash flow heavily depends on sustaining the strong 31% YoY growth of TAVALISSE and REZLIDHIA, which together constituted over 75% of net product sales in Q1 2026. Any deceleration below 15-20% in these key products could quickly revert the company to cash burn, especially as the Lilly RIPK1 collaboration termination removes future milestone payments and adds development costs for regaining full rights post-June 2026.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
High reliance on two primary commercial products (TAVALISSE and REZLIDHIA) for over 75% of net product sales, leading to concentration risk.
- ⚠
Termination of the Eli Lilly RIPK1 collaboration removes a partnered pipeline asset and potential future milestone payments, shifting development burden and costs back to Rigel.
- ⚠
Approval for adding 500,000 shares to the equity incentive plan and 360,000 to the ESPP on May 14, 2026, represents ongoing, albeit minor, share dilution.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Report (estimated late July/early August 2026): If combined TAVALISSE and REZLIDHIA sales growth decelerates below 15% YoY, signaling commercial stagnation.
- 📅
Competitive entrants or label expansion for rivals in ITP or AML (within next 12-18 months): Potential erosion of TAVALISSE or REZLIDHIA market share, impacting a significant portion of Rigel's revenue.
When to Reconsider
- 🚪
Exit if combined quarterly net product sales growth for TAVALISSE and REZLIDHIA falls below 15% year-over-year for two consecutive quarters.
- 🚪
Sell if cash, cash equivalents, and short-term investments drop below $100 million in any quarterly report without a clear, immediate financing plan.
Unlock RIGL Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Rigel Pharmaceuticals Inc (RIGL) Do?
Market Cap
$539.71M
Sector
Healthcare
Industry
Biotechnology
Employees
162
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Visit Rigel Pharmaceuticals Inc WebsiteInvestment Thesis
If Rigel maintains 25%+ YoY growth for TAVALISSE and REZLIDHIA, driving combined annual net product sales to $300M+ by late FY2027 while sustaining operating margins above 15% and effectively managing the regained RIPK1 assets, the company's valuation could re-rate to 5-7x Price/Sales, implying a market cap of $1.5B-$2.1B (3-4x current) and a potential path towards 10x if pipeline assets yield successful clinical development or a new partnership.
Is RIGL Stock Undervalued?
Unlock the full AI analysis for RIGL
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
RIGL Price Targets & Strategy
12-Month Target
$45.67
Bull Case
$60.00
Bear Case
$20.00
Valuation Basis
Analyst consensus target of $45.67, implying a ~26x P/E multiple on estimated annualized Q1 2026 EPS of $1.76 ($0.44 * 4).
Entry Strategy
Dollar-cost average between $27-$30, aiming for entries on pullbacks towards potential support levels.
Exit Strategy
Consider profit-taking 50% of position at $45-$50. Implement a stop-loss order if share price drops below $25.00.
Portfolio Allocation
5% for moderate risk tolerance, given the improved financial health but continued small-cap biotech volatility.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is RIGL Financially Healthy?
Valuation
P/E Ratio
1.48
Forward P/E
16.38
EV/EBITDA
7.01
PEG Ratio
9.15
Price/Book
18.24
Price/Sales
1.67
Profitability
Gross Margin
93.39%
Operating Margin
41.56%
Net Margin
121.51%
Return on Equity
147.03%
Revenue Growth
47.61%
EPS
$18.43
Balance Sheet
Current Ratio
2.42
Quick Ratio
2.08
Debt/Equity
0.13
Cash & Equivalents
$146.70M
Cash Flow
Free Cash Flow
$79.00M
Other
Beta (Volatility)
1.20
Does RIGL Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
Rigel's moat is primarily driven by patent protection for its approved drugs, offering a period of exclusivity in their respective niche markets. The established clinical efficacy and safety profiles of TAVALISSE and REZLIDHIA create switching costs for physicians and patients. This moat is durable for the lifespan of its patents, typically 10-15 years post-approval, but can be eroded by new, more effective therapies.
Moat Erosion Risks
- •Expiration of key product patents (TAVALISSE, REZLIDHIA) leading to generic competition.
- •Emergence of superior or equally effective therapies from larger competitors with greater R&D and commercialization resources.
- •Pricing pressures or changes in reimbursement policies for rare disease drugs.
RIGL Competitive Moat Analysis
Sign up to see competitive advantages
RIGL Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, typical for a small-cap biotech focused on niche markets, lacking widespread retail investor discussion.
Institutional Sentiment
Positive, indicated by a 'Moderate Buy' analyst consensus (3 Buy, 3 Hold, 0 Sell) and a recent upgrade by Zacks from 'Strong Sell' to 'Hold' in February 2026. High institutional ownership at 93.79% suggests strong professional conviction.
Insider Activity (Form 4)
Kamil Ali-Jackson (Director) received 5,750 RSUs as compensation, reported on May 19, 2026. No open-market buy/sell activity by CEO/CFO or other insiders verified in the last 90 days from the provided research.
Options Flow
Normal options activity, with no specific unusual put/call ratio or large block trades identified in the provided research.
Earnings Intelligence
Next Earnings
Estimated early-August 2026
Surprise Probability
Medium
Historical Earnings Pattern
Q1 2026 revenue and EPS both missed analyst estimates, but actual results showed a significant swing to profitability. No consistent stock price reaction pattern identified from provided data to prior earnings reports.
Key Metrics to Watch
Competitive Position
Top Competitor
JAZZ
Market Share Trend
Gaining market share in its niche indications for TAVALISSE and REZLIDHIA, evidenced by 31% YoY product sales growth for both.
Valuation vs Peers
Trading at a P/E multiple of ~15.5x (based on annualized Q1 2026 net income) and P/S multiple of ~2.3x (based on annualized Q1 2026 revenue). These are generally below the average for high-growth biotechs with established product portfolios, suggesting a discount that may re-rate if profitability is sustained.
Competitive Advantages
- •Approved and commercialized proprietary small molecule drugs (TAVALISSE, REZLIDHIA) addressing unmet needs in rare diseases.
- •Established commercial infrastructure and physician relationships in niche hematology/oncology markets.
- •Focused R&D approach on targeted therapies with clear mechanisms of action.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive RIGL Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (estimated late July/early August 2026): Continued 25%+ YoY growth for TAVALISSE and REZLIDHIA sales, driving overall net product sales above $65M.
- •Successful re-integration of RIPK1 assets into pipeline (post-June 15, 2026): A clear announcement of a new development path or early-stage partnership for the global rights.
Medium-Term (6-18 months)
- •Regulatory approval for REZLIDHIA in wAIHA (Warm Autoimmune Hemolytic Anemia, if still pending): Potential for significant expansion of REZLIDHIA's total addressable market and revenue base by 20-30%.
- •New strategic partnership or licensing deal for a pipeline asset (FY2027): Validation of Rigel's R&D capabilities and potential for non-dilutive funding or milestone payments.
Long-Term (18+ months)
- •Full commercialization and market penetration of REZLIDHIA and TAVALISSE in key international markets (FY2028-2029): Driving combined annual net product sales over $500M and establishing market leadership in rare hematology/oncology niches.
- •Advancement of a next-generation pipeline candidate into Phase 2/3 clinical trials (FY2029-2030): Opens new blockbuster potential beyond current approved assets and diversifies revenue streams.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for RIGL?
- ✓
Watch quarterly combined TAVALISSE and REZLIDHIA sales growth: consistently above 25% YoY signals continued market penetration and commercial strength.
- ✓
Monitor operating cash flow: sustained positive operating cash flow above $5M/quarter indicates healthy financial self-sufficiency.
- ✓
Updates on the RIPK1 program post-Lilly termination: a clear development plan or new partnership by Q4 2026 would reduce pipeline uncertainty.
Bull Case Analysis
Sign up free to see the bull case
Competing with RIGL
See how Rigel Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Rigel Pharmaceuticals Inc RIGL | $539.7M | 7.0 | 1.5 | $203.1M | 121.5% | 47.6% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Jazz Pharmaceuticals PLC JAZZ | $11.9B | 0.7 | -33.3 | $4.2B | -8.3% | 4.9% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Rigel Pharmaceuticals Inc Makes Money
Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing innovative small molecule drugs for rare diseases and oncology. It primarily generates revenue through the direct sales of its two main approved products: TAVALISSE, used to treat chronic immune thrombocytopenia (ITP), and REZLIDHIA, for relapsed/refractory acute myeloid leukemia (AML) with an IDH1 mutation. Additionally, Rigel earns revenue from collaborations, such as the licensing of GAVRETO for RET-altered cancers to a partner. The company's business model is centered on identifying unmet medical needs in niche, high-value markets, developing targeted therapies, and bringing them to market through its own commercial infrastructure or strategic partnerships.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Rigel Pharmaceuticals Inc (RIGL)?
As of May 23, 2026, Rigel Pharmaceuticals Inc has a DVR Score of 7.0 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Rigel Pharmaceuticals Inc?
Rigel Pharmaceuticals Inc's market capitalization is approximately $539.7M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Rigel Pharmaceuticals Inc use?
RIGL is the ticker symbol for Rigel Pharmaceuticals Inc. The company trades on the NMS.
What is the risk level for RIGL stock?
Our analysis rates Rigel Pharmaceuticals Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of RIGL?
Rigel Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of 1.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Rigel Pharmaceuticals Inc's revenue growing?
Rigel Pharmaceuticals Inc has reported revenue growth of 47.6%. The company is showing strong top-line momentum.
Is RIGL stock profitable?
Rigel Pharmaceuticals Inc has a profit margin of 121.5%. This indicates strong profitability.
How often is the RIGL DVR analysis updated?
Our AI-powered analysis of Rigel Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 23, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RIGL (Rigel Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.